Reliability of the CMT Neuropathy Score (second Version) in Charcot-Marie-Tooth Disease

Overview

Journal J Peripher Nerv Syst

Publisher Wiley

Specialty Neurology

Date 2011 Oct 19

PMID 22003934

Citations 154

Authors

Sinead M Murphy

David N Herrmann

Michael P McDermott

Steven S Scherer

Michael E Shy

Mary M Reilly

Davide Pareyson

Affiliations

Soon will be listed here.

Abstract

The Charcot-Marie-Tooth neuropathy score (CMTNS) is a reliable and valid composite score comprising symptoms, signs, and neurophysiological tests, which has been used in natural history studies of CMT1A and CMT1X and as an outcome measure in treatment trials of CMT1A. Following an international workshop on outcome measures in Charcot-Marie-Tooth disease (CMT), the CMTNS was modified to attempt to reduce floor and ceiling effects and to standardize patient assessment, aiming to improve its sensitivity for detecting change over time and the effect of an intervention. After agreeing on the modifications made to the CMTNS (CMTNS2), three examiners evaluated 16 patients to determine inter-rater reliability; one examiner evaluated 18 patients twice within 8 weeks to determine intra-rater reliability. Three examiners evaluated 63 patients using the CMTNS and the CMTNS2 to determine how the modifications altered scoring. For inter- and intra-rater reliability, intra-class correlation coefficients (ICCs) were ≥0.96 for the CMT symptom score and the CMT examination score. There were small but significant differences in some of the individual components of the CMTNS compared with the CMTNS2, mainly in the components that had been modified the most. A longitudinal study is in progress to determine whether the CMTNS2 is more sensitive than the CMTNS for detecting change over time.

Citing Articles

Disease Progression in Charcot-Marie-Tooth Disease Type 4B (CMT4B) Associated With Mutations in Myotubularin-Related Proteins 2 and 13.

Bertini A, Reilly M, Pisciotta C, Previtali S, Parman Y, Battaloglu E Eur J Neurol. 2025; 32(2):e70084.

PMID: 39943887 PMC: 11822262. DOI: 10.1111/ene.70084.

Heterozygous PNPT1 Variants Cause a Sensory Ataxic Neuropathy.

Haddad S, Record C, Self E, Skorupinska M, Rossor A, Laura M Eur J Neurol. 2025; 32(2):e70064.

PMID: 39924761 PMC: 11807841. DOI: 10.1111/ene.70064.

Evaluating plasma biomarkers NfL, GFAP, GDF15, and FGF21 as indicators of disease severity in Charcot-Marie Tooth patients.

Pretkalnina D, Kenina E, Gailite L, Rots D, Blennow K, Zetterberg H Front Neurol. 2025; 15:1490024.

PMID: 39882365 PMC: 11774688. DOI: 10.3389/fneur.2024.1490024.

A Novel Variant in a Charcot-Marie-Tooth Type 2: Insights from Familial Analysis.

Ciampana V, Corrado L, Magistrelli L, Contaldi E, Comi C, DAlfonso S Genes (Basel). 2025; 15(12.

PMID: 39766823 PMC: 11675712. DOI: 10.3390/genes15121556.

Electrophysiological Monitoring of Asymptomatic Transthyretin Mutation Carriers.

Berard N, Verschueren A, Fortanier E, Grapperon A, Kouton L, Rebouh H Muscle Nerve. 2024; 71(2):208-215.

PMID: 39668650 PMC: 11708451. DOI: 10.1002/mus.28318.

References

Verhamme C, van Schaik I, Koelman J, de Haan R, Vermeulen M, de Visser M . Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol. 2005; 251(12):1491-7. DOI: 10.1007/s00415-004-0578-x. View

Nicholson G, Myers S . Intermediate forms of Charcot-Marie-Tooth neuropathy: a review. Neuromolecular Med. 2006; 8(1-2):123-30. DOI: 10.1385/nmm:8:1-2:123. View

Reilly M, De Jonghe P, Pareyson D . 136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands. Neuromuscul Disord. 2006; 16(6):396-402. DOI: 10.1016/j.nmd.2006.03.008. View

Shy M, Blake J, Krajewski K, Fuerst D, Laura M, Hahn A . Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology. 2005; 64(7):1209-14. DOI: 10.1212/01.WNL.0000156517.00615.A3. View

Shy M, Siskind C, Swan E, Krajewski K, Doherty T, Fuerst D . CMT1X phenotypes represent loss of GJB1 gene function. Neurology. 2007; 68(11):849-55. DOI: 10.1212/01.wnl.0000256709.08271.4d. View

Micallef J, Attarian S, Dubourg O, Gonnaud P, Hogrel J, Stojkovic T . Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2009; 8(12):1103-10. DOI: 10.1016/S1474-4422(09)70260-1. View

Sahenk Z, Chen L . Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts. J Neurosci Res. 1998; 51(2):174-84. DOI: 10.1002/(SICI)1097-4547(19980115)51:2<174::AID-JNR6>3.0.CO;2-A. View

Kong X, Lesser E, Gozani S . Repeatability of nerve conduction measurements derived entirely by computer methods. Biomed Eng Online. 2009; 8:33. PMC: 2777171. DOI: 10.1186/1475-925X-8-33. View

Ven A, Van Hees J, Stappaerts K . Intra-examiner reliability of sensory nerve conduction measurements. Acta Neurol Belg. 2009; 108(4):139-42. View

10.

Whitton T, Johnson R, Lovell A . Use of the Rydel-Seiffer graduated tuning fork in the assessment of vibration threshold in postherpetic neuralgia patients and healthy controls. Eur J Pain. 2005; 9(2):167-71. DOI: 10.1016/j.ejpain.2004.05.001. View

11.

Lewelt A, Krosschell K, Scott C, Sakonju A, Kissel J, Crawford T . Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle Nerve. 2010; 42(5):703-8. PMC: 2964439. DOI: 10.1002/mus.21838. View

12.

Bergin P, Bronstein A, Murray N, Sancovic S, Zeppenfeld D . Body sway and vibration perception thresholds in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry. 1995; 58(3):335-40. PMC: 1073371. DOI: 10.1136/jnnp.58.3.335. View

13.

Pestronk A, Florence J, Levine T, Al-Lozi M, Lopate G, Miller T . Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude. Neurology. 2004; 62(3):461-4. DOI: 10.1212/01.wnl.0000106939.41855.36. View

14.

Shrout P, Fleiss J . Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979; 86(2):420-8. DOI: 10.1037//0033-2909.86.2.420. View

15.

Harding A, Thomas P . The clinical features of hereditary motor and sensory neuropathy types I and II. Brain. 1980; 103(2):259-80. DOI: 10.1093/brain/103.2.259. View

16.

Padua L, Pareyson D, Aprile I, Cavallaro T, Quattrone A, Rizzuto N . Natural history of CMT1A including QoL: a 2-year prospective study. Neuromuscul Disord. 2008; 18(3):199-203. DOI: 10.1016/j.nmd.2007.11.008. View

17.

Verhamme C, van Schaik I, Koelman J, de Haan R, de Visser M . The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study. Brain. 2009; 132(Pt 12):3252-62. DOI: 10.1093/brain/awp251. View

18.

Martina I, van Koningsveld R, Schmitz P, van der Meche F, van Doorn P . Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry. 1998; 65(5):743-7. PMC: 2170371. DOI: 10.1136/jnnp.65.5.743. View

19.

Pareyson D, Reilly M, Schenone A, Fabrizi G, Cavallaro T, Santoro L . Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 2011; 10(4):320-8. PMC: 3154498. DOI: 10.1016/S1474-4422(11)70025-4. View

20.

Shy M, Chen L, Swan E, Taube R, Krajewski K, Herrmann D . Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology. 2008; 70(5):378-83. DOI: 10.1212/01.wnl.0000297553.36441.ce. View